GT200400226A - Compuestos de pirazolilo e imidazolilo biciclicos y usos de los mismos - Google Patents

Compuestos de pirazolilo e imidazolilo biciclicos y usos de los mismos

Info

Publication number
GT200400226A
GT200400226A GT200400226A GT200400226A GT200400226A GT 200400226 A GT200400226 A GT 200400226A GT 200400226 A GT200400226 A GT 200400226A GT 200400226 A GT200400226 A GT 200400226A GT 200400226 A GT200400226 A GT 200400226A
Authority
GT
Guatemala
Prior art keywords
compounds
pirazolilo
imidazolilo
bicycle
same
Prior art date
Application number
GT200400226A
Other languages
English (en)
Spanish (es)
Inventor
Philip Albert Carpino
Robert Lee Dow
David Andrew Griffith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200400226A publication Critical patent/GT200400226A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GT200400226A 2003-11-07 2004-11-04 Compuestos de pirazolilo e imidazolilo biciclicos y usos de los mismos GT200400226A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51828003P 2003-11-07 2003-11-07

Publications (1)

Publication Number Publication Date
GT200400226A true GT200400226A (es) 2005-09-06

Family

ID=34572986

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200400226A GT200400226A (es) 2003-11-07 2004-11-04 Compuestos de pirazolilo e imidazolilo biciclicos y usos de los mismos

Country Status (29)

Country Link
US (2) US7151097B2 (enExample)
EP (1) EP1682554A1 (enExample)
JP (2) JP4056549B2 (enExample)
KR (1) KR20060086396A (enExample)
CN (1) CN1886407A (enExample)
AP (1) AP2006003601A0 (enExample)
AR (1) AR046831A1 (enExample)
AU (1) AU2004286909A1 (enExample)
BR (1) BRPI0416299A (enExample)
CA (1) CA2544752A1 (enExample)
CR (1) CR8387A (enExample)
DO (1) DOP2004001024A (enExample)
EA (1) EA009742B1 (enExample)
EC (1) ECSP066549A (enExample)
GT (1) GT200400226A (enExample)
HR (1) HRP20060166A2 (enExample)
IL (1) IL175283A0 (enExample)
IS (1) IS8426A (enExample)
MA (1) MA28151A1 (enExample)
MX (1) MXPA06005023A (enExample)
NL (1) NL1027434C2 (enExample)
NO (1) NO20062618L (enExample)
OA (1) OA13280A (enExample)
PA (1) PA8616801A1 (enExample)
PE (1) PE20050576A1 (enExample)
TN (1) TNSN06129A1 (enExample)
TW (2) TWI280245B (enExample)
WO (1) WO2005044822A1 (enExample)
ZA (1) ZA200603594B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
US7094572B2 (en) * 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
MX2007003586A (es) * 2004-09-27 2007-05-21 Pfizer Prod Inc Procedimiento para preparar compuestos de pirazolilo biciclicos.
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
WO2006111849A1 (en) * 2005-04-20 2006-10-26 Pfizer Products Inc. Acylaminobicyclic heteromatic compounds as cannabinoid receptor ligands
CA2609783A1 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US7872006B2 (en) 2005-10-21 2011-01-18 Mitsubishi Tanabe Pharma Corporation Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity
WO2007060525A2 (en) 2005-11-28 2007-05-31 Pfizer Products Inc. Process for preparing bicyclic pyrazolyl and imidazolyl compounds
AU2007219236B2 (en) * 2006-02-23 2012-06-21 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
JP5528699B2 (ja) * 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
WO2008048648A2 (en) * 2006-10-17 2008-04-24 Acadia Pharmaceuticals Inc. Cb1-modulating compounds and their use
CA2669311C (en) 2006-11-13 2011-09-20 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
US20090062253A1 (en) * 2007-08-31 2009-03-05 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
ES2421920T3 (es) * 2008-08-06 2013-09-06 Pfizer Ltd Compuestos de diazepina y diazocano como agonistas de MC4
US9549006B2 (en) * 2013-07-31 2017-01-17 Cisco Technology, Inc. Self-adaptive sample period for content sharing in communication sessions
CN109810104B (zh) * 2013-11-08 2022-05-03 因赛特控股公司 用于合成吲哚胺2,3-双加氧酶抑制剂的方法
WO2020060761A2 (en) 2018-09-04 2020-03-26 Skodda Anja Pet food formulation with cannabinoids
US11504416B2 (en) 2018-09-04 2022-11-22 Paw Power, Inc. Formulation with cannabinoids
JP7516697B2 (ja) * 2019-08-09 2024-07-17 日本農薬株式会社 オキサゼピノン誘導体及び該誘導体を含有する農園芸用殺虫剤並びにその使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
JP2005507875A (ja) 2001-08-31 2005-03-24 ユニバーシティ オブ コネチカット カンナビノイド受容体に作用する新規なピラゾール類似体
CA2461142A1 (en) 2001-09-24 2003-04-03 Bayer Pharmaceuticals Corporation Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
GB0207249D0 (en) 2002-03-27 2002-05-08 Glaxo Group Ltd Novel compounds
WO2004035566A1 (en) 2002-10-18 2004-04-29 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7423031B2 (en) 2003-05-01 2008-09-09 Irm Llc Compounds and compositions as protein kinase inhibitors
MXPA05011922A (es) 2003-05-07 2006-02-17 Pfizer Prod Inc Ligandos del receptor de cannabinoides y sus usos.
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US20050026983A1 (en) 2003-07-30 2005-02-03 Pfizer Inc Imidazole compounds and uses thereof
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
MX2007003586A (es) * 2004-09-27 2007-05-21 Pfizer Prod Inc Procedimiento para preparar compuestos de pirazolilo biciclicos.

Also Published As

Publication number Publication date
CN1886407A (zh) 2006-12-27
CA2544752A1 (en) 2005-05-19
US7151097B2 (en) 2006-12-19
US20050101592A1 (en) 2005-05-12
KR20060086396A (ko) 2006-07-31
EA200600647A1 (ru) 2006-10-27
ECSP066549A (es) 2006-10-17
JP2007302685A (ja) 2007-11-22
MA28151A1 (fr) 2006-09-01
PE20050576A1 (es) 2005-09-14
HRP20060166A2 (en) 2006-10-31
TWI280245B (en) 2007-05-01
NL1027434A1 (nl) 2005-05-10
EP1682554A1 (en) 2006-07-26
NO20062618L (no) 2006-08-07
BRPI0416299A (pt) 2007-01-23
TNSN06129A1 (fr) 2007-11-15
AP2006003601A0 (en) 2006-04-30
JP4056549B2 (ja) 2008-03-05
US20070027133A1 (en) 2007-02-01
OA13280A (en) 2007-01-31
ZA200603594B (en) 2007-09-26
AR046831A1 (es) 2005-12-28
TW200716135A (en) 2007-05-01
PA8616801A1 (es) 2006-05-16
IS8426A (is) 2006-04-21
CR8387A (es) 2007-05-30
JP2007510707A (ja) 2007-04-26
EA009742B1 (ru) 2008-04-28
AU2004286909A1 (en) 2005-05-19
IL175283A0 (en) 2006-09-05
TW200526669A (en) 2005-08-16
WO2005044822A1 (en) 2005-05-19
NL1027434C2 (nl) 2007-11-27
DOP2004001024A (es) 2005-05-14
MXPA06005023A (es) 2006-07-06

Similar Documents

Publication Publication Date Title
GT200400226A (es) Compuestos de pirazolilo e imidazolilo biciclicos y usos de los mismos
GT200400078A (es) Ligandos del receptor cannabinoide y usos de los mismos
GT200400013A (es) Compuestos de pirazolotriazina y usos de los mismos
GT200300232A (es) Compuestos de purina y usos de los mismos
GT200500101A (es) Compuestos de metil-aril o heteroaril-amida sustituida
HN2008000178A (es) Compuestos triciclicos, composiciones y procedimientos
CL2004000861A1 (es) Compuesto biciclico derivado de pirazol [4,3-d] pirimidin-7-ona o de pirazol [4,3-c] piridin-7-ona de formula definida, como ligando del receptor cannabinoide que actua como antagonista del receptor cb1; composicion farmaceutica que comprende al comp
PA8662501A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como agentes selectivos de 5ht2a
PT2570128T (pt) Antagonistas do receptor muscarínico de acetilcolina
GT200500185A (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
UY28276A1 (es) Ligandos de receptores de cannabinoides y sus usos
SMP200600024B (it) 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosina
GT200600453A (es) Indoles de acilo, composiciones que contienen dichos compuestos y procedimientos de uso
GT200600024A (es) Derivados de triazol sustituidos como antagonistas de oxitocina
PE20070246A1 (es) Compuestos de pirazolina sustituidos como moduladores del receptor cb1 y su preparacion
DK1749921T3 (da) Brandhæmmende, syntetisk læder
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
GT200400041A (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol
GT200400188A (es) 5-arilpirimidinas como agentes anticancerigenos
SG144934A1 (en) C5a receptor antagonists
BR0312378A (pt) Moduladores de receptores de cck-1
TW200706530A (en) Organic electroluminescent device
ITMI20031292A1 (it) Derivati biciclici nk-2 antagonisti selettivi.
IL187915A0 (en) 1,2-di(cyclic group)substituted benzene derivative
GB2432605A (en) Expandable tubular